BridgeBio rises as its genetic disease drug meets goals in late-stage trial
29/10/2025 11:27
** Shares of drugmaker BridgeBio Pharma BBIO.O rise 8.6% to $70.00 premarket ** Co says its drug, encaleret, for genetic condition autosomal dominant hypocalcemia type 1, or ADH1, met all main and secondary goals in late-stage trial ** ADH1 is a rare genetic disease that causes low blood calcium and kidney problems ** BBIO says 76% of patients on encaleret hit both blood and urine calcium targets vs 4% on standard therapy ** Adds that 91% on encaleret had normal parathyroid hormone levels vs 7% on standard therapy ** BBIO to apply for U.S. approval of encaleret in first half of 2026 and will also seek European approval ** Up to last close, stock up ~135% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels